PMID- 23455182
OWN - NLM
STAT- MEDLINE
DCOM- 20140610
LR  - 20161020
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 21
IP  - 6
DP  - 2013 Dec
TI  - HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: 
      comparison of automated dual ISH to FISH.
PG  - 561-6
LID - 10.1097/PAI.0b013e3182849826 [doi]
AB  - Patients with gastric and gastroesophageal junction (GEJ) adenocarcinomas that 
      are HER2 positive by immunohistochemistry (IHC) or in situ hybridization show a 
      significant survival benefit with trastuzumab therapy. In situ hybridization is 
      traditionally done by fluorescence in situ hybridization (FISH), despite some 
      limitations. An alternative is the dual in situ hybridization (Dual ISH) 
      technique that is fully automated and uses differentially labeled CEP17 and HER2 
      probes that can be read by light microscopy on 1 slide. The aim of this study was 
      to assess the utility of Dual ISH in gastric/GEJ cancer and to compare the 
      results with those obtained by IHC and FISH. Cases of gastric/GEJ adenocarcinoma 
      were analyzed by IHC, FISH, and Dual ISH and the correlation between methods 
      calculated. Results for 50 patients were available. There was a 98% (49/50) 
      concordance rate between Dual ISH and FISH. One discrepant case was nonamplified 
      by FISH but showed focal amplification by Dual ISH. Discrepancy was attributed to 
      tumor heterogeneity, which was a frequent finding (78% of HER2-positive cases). 
      There was excellent correlation between Dual ISH and FISH for assessment of HER2 
      amplification. Dual ISH was rapid, easy to interpret, and maintained cell 
      morphology, which was valuable in identifying tumor heterogeneity.
FAU - Grin, Andrea
AU  - Grin A
AD  - *Department of Medical Oncology, St. Michael's Hospital and University of 
      Toronto, Toronto, ON, Canada daggerDepartment of Laboratory Medicine, the Li Ka Shing 
      Knowledge Institute.
FAU - Brezden-Masley, Christine
AU  - Brezden-Masley C
FAU - Bauer, Sharon
AU  - Bauer S
FAU - Streutker, Catherine J
AU  - Streutker CJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - Adenocarcinoma Of Esophagus
SB  - IM
MH  - Adenocarcinoma/*diagnosis/genetics/pathology
MH  - Automation, Laboratory
MH  - Biomarkers, Tumor/*genetics
MH  - Centromere/chemistry
MH  - Chromosomes, Human, Pair 17
MH  - Esophageal Neoplasms/*diagnosis/genetics/pathology
MH  - Esophagogastric Junction/metabolism/pathology
MH  - Humans
MH  - In Situ Hybridization/*methods
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*genetics
MH  - Stomach Neoplasms/*diagnosis/genetics/pathology
EDAT- 2013/03/05 06:00
MHDA- 2014/06/11 06:00
CRDT- 2013/03/05 06:00
PHST- 2013/03/05 06:00 [entrez]
PHST- 2013/03/05 06:00 [pubmed]
PHST- 2014/06/11 06:00 [medline]
AID - 10.1097/PAI.0b013e3182849826 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):561-6. doi: 
      10.1097/PAI.0b013e3182849826.